Compare · GH vs NTRA
GH vs NTRA
Side-by-side comparison of Guardant Health Inc. (GH) and Natera Inc. (NTRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GH and NTRA operate in Medical Specialities (Health Care), so they compete in similar markets.
- NTRA is the larger of the two at $41.98B, about 2.1x GH ($19.64B).
- NTRA has been more active in the news (33 items in the past 4 weeks vs 25 for GH).
- Both have 25 recent analyst ratings on file.
- Company
- Guardant Health Inc.
- Natera Inc.
- Price
- -
- -
- Market cap
- $19.64B
- $41.98B
- 1M return
- -
- -28.69%
- 1Y return
- -
- +35.40%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2015
- News (4w)
- 25
- 33
- Recent ratings
- 25
- 25
Guardant Health Inc.
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing tests from its LUNAR program for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; LUNAR-2 test for the early detection of cancer in asymptomatic individuals eligible for cancer screening; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for residual disease and recurrence monitoring; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. Daiichi Sankyo has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Latest GH
- Director Medina Manuel Hidalgo converted options into 232 shares, increasing direct ownership by 4% to 5,484 units (SEC Form 4)
- Director Alex M Azar II sold $10,320 worth of shares (69 units at $149.56), decreasing direct ownership by 7% to 962 units (SEC Form 4)
- Director Musa Tariq converted options into 250 shares and sold $17,349 worth of shares (116 units at $149.56), increasing direct ownership by 1% to 11,717 units (SEC Form 4)
- Guardant Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits
- Director Azar Alex M Ii converted options into 138 shares, increasing direct ownership by 15% to 1,031 units (SEC Form 4)
- Director Sayer Kevin R was granted 3,149 restricted stock units (SEC Form 4)
- Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- New insider Sayer Kevin R claimed no ownership of stock in the company (SEC Form 3)
- Chief Accounting Officer Parks Robert was granted 18,893 restricted stock units (SEC Form 4)
- New insider Parks Robert claimed no ownership of stock in the company (SEC Form 3)
Latest NTRA
- HLTH 2026 Names Natera Best-in-Class Winner in Cancer, Screening & Early Detection
- Amendment: SEC Form SCHEDULE 13G/A filed by Natera Inc.
- CO-FOUNDER Sheena Jonathan sold $478,945 worth of shares (1,500 units at $319.30) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form S-3ASR filed by Natera Inc.
- SEC Form S-8 filed by Natera Inc.
- CO-FOUNDER Sheena Jonathan sold $975,623 worth of shares (3,086 units at $316.14) as part of a pre-agreed trading plan and sold $19,781 worth of Common Stock (64 units at $309.08) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 214,462 units (SEC Form 4)
- Natera Announces Clinical Collaboration with Incyte on Interventional Phase II Study in Colorectal Cancer
- Amendment: SEC Form SCHEDULE 13G/A filed by Natera Inc.
- SEC Form 10-Q filed by Natera Inc.
- Natera Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits